Article

Prerolled IOL appropriate option for high-risk uveitic eyes

Norfolk, VA-The CV232 Memory- Lens (Ciba Vision) is an appropriatechoice for IOL implantation after cataract surgery in patients with intraocularinflammation, said John D. Sheppard, MD, MMSc, professor of ophthalmology,microbiology, and molecular cell biology, Eastern Virginia Medical School,Norfolk.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
Related Content
Health Canada approves Biocon's Yesafili, biosimilar to Eylea
July 1st 2025

Health Canada approves Biocon's Yesafili, biosimilar to Eylea

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Nicox completes phase 3 Denali trial of NCX 470 in open-angle glaucoma or ocular hypertension
June 30th 2025

Nicox completes phase 3 Denali trial of NCX 470 in open-angle glaucoma or ocular hypertension

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

Nanoscope Therapeutics forms Vision Advisory Committee
June 30th 2025

Nanoscope Therapeutics forms Vision Advisory Committee

Sanaregen Vision Therapeutics invites prospective investors to reserve stock shares
June 29th 2025

Sanaregen Vision Therapeutics invites prospective investors to reserve stock shares

© 2025 MJH Life Sciences

All rights reserved.